Related Experiment Video
Updated: Jun 21, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
38.9K
Deucravacitinib: moderate-to-severe plaque psoriasis preventable?
1Department of Pharmacology, Kalpana Chawla Government Medical College, Karnal, Haryana, India.
Summary
Deucravacitinib, a selective oral TYK2 inhibitor, offers a new treatment option for moderate-to-severe plaque psoriasis. This review examines its efficacy and safety for managing this chronic autoimmune condition.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Psoriasis is a chronic, inflammatory autoimmune disease with variable prevalence.
- Current treatments include topical therapies, phototherapy, and systemic agents, but limitations exist.
- There is an ongoing need for innovative and effective psoriasis therapies.
Purpose of the Study:
- To review the efficacy and safety of deucravacitinib for psoriasis management.
- To provide an overview of deucravacitinib's mechanism of action.
- To discuss its potential role in treating immune-mediated conditions.
Main Methods:
- Review of current knowledge on deucravacitinib.
- Analysis of its mechanism as a selective tyrosine kinase 2 (TYK2) inhibitor.
- Examination of its approval and application in plaque psoriasis treatment.
Main Results:
- Deucravacitinib is a first-in-class oral selective TYK2 inhibitor.
- It works by allosterically stabilizing an inhibitory connection within TYK2.
- US-FDA approved deucravacitinib in September 2022 for moderate-to-severe plaque psoriasis.
Conclusions:
- Deucravacitinib represents a novel therapeutic approach for psoriasis.
- Its selective TYK2 inhibition offers a new mechanism for immune-mediated disease treatment.
- Further data on long-term efficacy and safety in psoriasis management are anticipated.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
114
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
114
01:22Dose-Response Relationship: Potency and Efficacy
4.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.3K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156